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Polyglycosylceramides (PGCs), complex glycolipids containing up to 50 or more sugar residues, are recognized as the
minor components of the cell-surface membranes, but a knowledge on their tissue distribution, structure, and function is
limited. In this study, the binding of influenza viruses to preparations of PGCs was investigated using a TLC overlay assay
and a microwell adsorption assay. The ability of PGCs to bind influenza virus was dependent on the source from which
they were derived. Preparations of PGCs from human erythrocytes were found to support binding of A and B influenza virus
strains at a much lower concentration than sialyl-6-paragloboside and to be somewhat better receptors for these viruses
compared to the sialylglycoprotein fetuin. A high virus-binding activity of PGCs suggests that these species could potentially
serve as biologically important cell-surface receptors for influenza viruses. q 1996 Academic Press, Inc.
Influenza virus infection is initiated by attachment of glycosphingolipid species containing up to 50 or more
sugars (11–13).the virus to host cells due to specific interactions of the
As a first step, binding of influenza virus to PGC prepa-viral hemagglutinin with sialic acid-terminated oligosac-
rations was evaluated using a TLC overlay assay (14).charide chains expressed on cell-surface glycoproteins
The PGCs were prepared in the Department of Medicaland/or gangliosides [see (1–3) for a review]. In spite of
Biochemistry, Go¨teborg University, Sweden, as de-the early identification of sialic acid as an essential part
scribed in (13). As shown in Fig. 1, influenza virus boundof influenza virus cellular receptors, the biologically rele-
strongly to PGC fractions isolated from human erythro-vant receptor species on target cells have not been de-
cytes and human leukocytes. Both preparations con-fined. Gangliosides, glycosphingolipids bearing terminal
tained mixtures of highly polar components generally mi-sialic acid residues (4), are regarded as possible candi-
grating slower than brain gangliosides, with the leuko-dates since they were shown to support virus binding
cyte material being more enriched in faster migratingin several model assay systems (5–7) and to stimulate
species. The fastest migrating bands of the leukocyteexperimental viral infection in tissue culture cells and in
fraction overlapped with the GD1a region of bovine brainmice (8, 9).
gangliosides, as judged from several chromatographicInfluenza virus binding has been shown to depend on
runs. However, it was very difficult to draw conclusionsthe type of sialic acid, the sialyl-Gal linkage, and the
concerning the complexity and structure of these speciescarbohydrate core structure of gangliosides [see (10) for
because the chromatographic system was not suitablea review]. In a recent study (7) on influenza virus binding
for separation of less complex glycolipids. PGCs fromto gangliosides from human granulocytes using a TLC
erythrocytes contained on average 25 sugar residues peroverlay assay, three minor nonidentified most polar gan-
ceramide with 1 sialic acid residue per about 14 glycosylgliosides displayed stronger binding compared to gangli-
units, and the trailing appearance of this fraction on TLCoside species with shorter oligosaccharide chains (3– 7
plates is due to the complexity and microheterogeneitysugars). This finding prompted us to investigate adhesion
of the sugar chains. The presence of N-acetylneuraminicof influenza viruses to polyglycosylceramides (PGCs),
acid in erythrocyte and leukocyte preparations and the
glycosphingolipid nature of the fractions were confirmed,1 To whom reprint requests should be addressed at present address:
respectively, by electron impact ionization mass spec-Department of Virology and Molecular Biology, St. Jude Children’s Re-
trometry after permethylation and by endoglycocerami-search Hospital, 332 North Lauderdale, P.O. Box 318, Memphis, TN
38101. dase treatment (not shown) [for a detailed description of
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amounts than PGCs from human erythrocytes. As de-
tailed structural data on PGCs from different hosts are
not available, we cannot rationalize for possible con-
straints for virus binding to rabbit, dog, and bovine prepa-
rations.
The preparation of PGCs from human erythrocytes was
further tested for its ability to support the binding of differ-
ent influenza virus strains in a microwell adsorption
assay (15, 20). Figure 2 represents the data on binding
of human H1, H3, and type B influenza virus isolates to
PGCs, as well as to fetuin and to sialyl-a6-paragloboside
(Neu5Aca6Galb4GlcNAcb3Galb4Glcb1Cer; 6-SPG). 6-
FIG. 1. Binding of influenza virus to complex glycosphingolipids on SPG was isolated from the acid glycosphingolipid frac-
TLC plates. (A) Glycolipids visualized by 4-methoxybenzaldehyde stain tion of human meconium by chromatography on DEAE-for carbohydrates. (B) Glycolipids visualized by binding of the influenza
Sepharose followed by HPLC on a silicic acid columnvirus labeled with horseradish peroxidase (HRP). Lane 1, PGCs from
(21). The structure of this glycosphingolipid was con-human leukocytes, 10 mg; lane 2, PGCs from human erythrocytes, 10
mg; lane 3, bovine brain gangliosides (a mixture of GM1, GD1a, GD1b, firmed by negative-ion FAB mass spectrometry and pro-
and GT1b; Calbiochem, USA), 6 mg; and lane 4, gangliosides from ton NMR spectroscopy (not shown). In Fig. 2, amounts
human erythrocyte membranes recovered from the upper phase after of the compounds added per well of the microplate areFolch’s partition (18), 30 mg. The plates (silica gel 60 on aluminum;
expressed in respect to sialic acid, to facilitate a compari-Merck, Germany) were developed in chloroform/methanol/water,
son of their virus-binding activity. As shown in Fig. 2, at50:55:19 (17). The TLC overlay assay was performed as described
in (14). A/Chile/1/83 (H1N1) influenza virus propagated in 10-day-old least an order of magnitude lower concentration of sialic
embryonated hen eggs and purified by sucrose density gradient centrif- acid residues of PGCs added per well is required for the
ugation was labeled with HRP as described before for the preparation same virus binding compared to 6-SPG. PGCs are alsoof fetuin–HRP conjugates (15), with the labeled virus being separated
two to five times more potent receptors than fetuin. Al-from unconjugated HRP by a sucrose density gradient centrifugation.
though the values of the compound concentration in Fig.The conjugation with HRP did not alter the ability of the virus to bind
to sialylglycoproteins and to gangliosides compared to the initial virus 2 may not represent the real amounts adsorbed in the
preparation, as judged from their comparison in the microwell adsorp- wells due to a possible desorption during the washing
tion assay (data not shown). Five milliliters of the solution of labeled and blocking steps, we believe that the conclusion aboutvirus in PBS–BSA (20 mg/ml of virus protein) was applied to the TLC
the high virus binding activity of PGCs is correct. Indeed,plate for 2 hr at 47. After five washings with PBS, the virus binding was
less than 50% of the fetuin is desorbed under the assayvisualized using 3,3-diaminobenzidine as a substrate.
conditions as was estimated in the separate experiments
with the labeled fetuin preparation (data not shown).
Even with an assumption that no PGCs is desorbed atPGCs from human erythrocytes see (13)]. The binding of
virus to erythrocyte and leukocyte PGCs was to the entire all, the binding curves still indicate the same or a better
binding to PGCs compared to fetuin. In fact, substantialbands of the chromatogram, although some components
seemed to be more active than others (compare lanes desorption of PGCs could be expected, as these com-
pounds bear long highly soluble sugar chains anchored1A and 1B, Fig. 1). Mild acid treatment of the PGCs abol-
ished the binding, confirming the role of sialic acid in to the solid phase only via their ceramide portion. As to
6-SPG, its desorption should be lower than that of PGCsvirus–PGC interaction (not shown). There was no binding
of the influenza virus to brain gangliosides (lane 3) nor due to its poorer hydrophilicity. It can be suspected,
therefore, that the binding potency of PGCs in respect toto the upper phase ganglioside fraction isolated from
human erythrocytes according to the conventional proce- that of fetuin and to 6-SPG could be underestimated in
our assay.dure (16) and Folch’s partition (18) (lane 4). We do not
know at present if the complexity of the molecules is of 6-SPG is one of the most active receptor analogs for
influenza viruses among various ganglioside speciesimportance for the binding, but it seems likely that long
and branched multivalent carbohydrate chains provide tested previously (10), while fetuin displays a binding
capacity which is comparable in this assay to that ofbetter conditions for interaction with the virus than
shorter simple chains. various sialylglycoproteins (15). It can be concluded,
therefore, that human erythrocyte PGCs exposed on aPGCs isolated from rabbit intestine and from dog intes-
tine and complex gangliosides from bovine erythrocytes membrane-like assay surface are among the most potent
known binders of the influenza viruses.(19) were also tested in the TLC overlay assay and no
virus was bound under identical assay conditions (data PGCs are minor cell components, and their isolation
from biological materials is difficult and laborious. Ournot shown) despite the fact that they all, the same as
human PGCs, had type 2 (neolacto) carbohydrate chains present knowledge on the PGC distribution is limited to
only few cells and tissues, namely to human erythrocytesand contained sialic acid in comparable or higher
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FIG. 2. Binding of influenza viruses to polyglycosylceramides (solid lines), fetuin (dashed lines), and sialyl-6-paragloboside (dotted lines) adsorbed
in the wells of plastic microtiter plates. The human strains A/Chr/157/83M (H1N1), A/NIB/47/89M (H3N2), and B/Eng/222/82M isolated and propagated
solely in MDCK cells (22–24) were used. For the binding assay, 0–20 ng PGCs from human erythrocytes (13) (0–8.8 pmol in respect to sialic acid)
or 0 –130 pmol 6-SPG from human granulocytes (21) dissolved in 50 ml of methanolic solution containing 500 pmol egg lecithin and 500 pmol
cholesterol (auxiliary lipids used to provide for the natural membrane-like environment) was added to wells of polyvinylchloride microtiter plates
(Cook, USA) prepared in triplicate. Fetuin (Sigma Chemical Co., USA) was added in 50-ml solutions in water (0–0.25 mg of the protein per well,
which corresponded to 0–65 pmol of bound sialic acid residues (25)). For negative controls, the wells without coating (squares) and those coated
with auxiliary lipids alone (triangles) were used. The plates were incubated at 377 for 4–5 hr for evaporation of methanol and water. One hundred
microliters of 0.2% solution of BSA in phosphate-buffered saline (0.2% BSA) was added per well and incubated for 1 hr at 377. The wells were
emptied and 50 ml of virus suspensions in 0.2% BSA with a hemagglutinating titer of 32–128 was added. The plates were incubated at 47 for 2 hr
for virus adsorption, rinsed three to four times with ice-cold washing solution (WS: 0.21 PBS–0.02% Tween 80), and further incubated with 50 ml/
well of fetuin–horseradish peroxidase conjugate (15) in PBS–0.02% Tween 80 for 0.5 hr at 47. Unbound conjugate was removed by six washings
with WS, and the amount of bound conjugate was quantified using o-phenylenediamine as a substrate.
and leukocytes, rabbit erythrocytes, human placenta and viruses (30). In future studies on the molecular mecha-
nisms of these effects a possible involvement of PGCspancreatic carcinoma cells, pig stomach mucosa, and
rabbit and dog intestine (11–13 and references therein; should, therefore, also be considered.
Miller-Podraza and Karlsson, in preparation); their pres-
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